Board of Directors and Management

A non-executive board of directors providing their time on a pro-bono basis governs the National Stem Cell Foundation of Australia (NSCFA).
The current directors are:

  • Dr Graeme Blackman OAM, PhD, BSc (Hons), BD, MTheol, FTSE, FRACI, FAICD, FIoD (Non-Executive Director, Chairman)

    Chairman of the Company, Dr Blackman is a former Professor of Pharmaceutical Chemistry at the Victorian College of Pharmacy. He is presently Chairman of IDT Australia Ltd, an Australian Securities Exchange (ASX) listed public company operating in the pharmaceutical industry. In particular he has chaired the Australian Government’s Pharmaceuticals Industry Action Agenda, which developed a policy framework for the industry over a ten-year period. He was a director of the Australian Stem Cell Centre.

    Dr Blackman has been, or continues to be a member of various Commonwealth and State advisory committees and working groups in pharmaceuticals and biotechnology, including the Australian Biotechnology Advisory Council, the Pharmaceutical Industry Working Group and the Pharmaceutical Industry Strategy Group.

  • Emeritus Professor Graham Macdonald AM, MD, BS, BSc (Med), FRACP, FRCP, FANZCC (Non-Executive, Deputy Chairman)

    Deputy Chairman of the Company, Professor Macdonald brings a wealth of experience in clinical medicine, basic biomedical science and in the field of licensing and commercialisation to the Company. He has had an outstanding career first as an academic nephrologist, and then moving into the pharmaceutical industry with Merck Sharp and Dohme (Australia). During this time he successfully brokered a number of high profile agreements including a US$100 million-plus deal with AMRAD (now Zenyth Therapeutics) to develop a new asthma treatment.

    Graham is currently a director and Chairman of Vectus Biosciences Limited and director and chairman of Stem Cells Limited. In June 2012 Professor Macdonald received an Australian Queen's Birthday Honour in the General Division of the Order of Australia for ‘service to biomedical research in the areas of hypertension and renal disease, to medical education, to the promotion and awareness raising of organ donation, and as a mentor’.

  • Mr Stuart Gooley BComm (Melb) FCA, FCPA (Non-Executive Director)

    Chairman of the Finance, Audit and Risk Management Sub-committees, Mr Gooley had a 42 year period in the accounting profession with Arthur Andersen and Ernst &Young, and retired from public practice in 2008. During his career he was the Australian head of Andersen's Accounting and Audit practice and the Asia Pacific Risk Management Practice Director.  Mr Gooley was the Victorian State President of CPA Australia in 1994, and served on the Australian Auditing and Assurance Standards Board and the International Auditing Practices Committee.

    Outside of the accounting profession he has served on the board of two educational institutions, and is currently a director of Lahaina Holdings Pty Ltd, Tai Tam Investments Pty Ltd, Wilson Transformer Company and of Trinity College. He is also a member of the audit committee of the Victorian Department of Education and a member of the resources committee of the Royal Australian College of Surgeons. He was a director of the Australian Stem Cell Centre.

  • Dr Karin Tiedemann (Non-Executive Director)

    Dr Karin Tiedemann has served more than 30 years as a paediatric oncologist, clinical haematologist and head of the Bone Marrow Transplant Unit in the Children’s Cancer Centre / Haematology Oncology Department, at The Royal Children’s Hospital (RCH) in Melbourne. She has been involved in the development of clinical protocols for the treatment of children with acute leukaemia and solid tumours contributing to advances in treatment that have resulted not only in high cure rates but also a lowering of the long term side effects of cancer treatment for infants and children.

    Dr Tiedemann pioneered and established the bone marrow transplant program at the RCH and has performed hundreds of bone marrow and cord blood transplants for children with leukaemia and other blood disorders.  She was pivotal in establishing an umbilical cord blood stem cell bank at the RCH.

    Dr Tiedemann has served on the examination committee of the RACP ,  the Specialist Advisory Committee in Medical Oncology, the Executive Committees of the Medical Oncology Group of Australia, the Australian and NZ Children’s Haematology/Oncology Group, and the Medical Staff Association of RCH.  She remains a member of the BMDI CBB Management Committee, Auscord, the Clinical Ethics Response group at RCH and the Ethics Committee of the Australian Bone Marrow Donor Registry.

  • Associate Professor Caroline Gargett (Non-Executive Director)

    Associate Professor Gargett is currently Deputy Director (Women’s Health) at the Ritchie Centre and is also a National Health & Medical Research Council (NHMRC) Senior Research Fellow.

    In 2002 Associate Professor Gargett discovered adult stem cells in the endometrium, the lining of the uterus, changing our understanding of how the endometrium regenerates each month. She leads a collaborative project with the CSIRO Future Manufacturing Flagship to investigate the use of endometrial mesenchymal stem cells for a tissue engineering application in pelvic floor prolapse surgery. Her research findings are promising for the development of potential therapeutics.

    Associate Professor Gargett has served as President of the Australasian Society for Stem Cell Research (2013-2014) and Secretary for the Society for Reproductive Biology (2005-2008). She is/has been on the Editorial Boards for Fertility and Sterility (2011-2014), Biology of Reproduction (since 2013), and Reproductive Sciences (since 2009) and is an Associate Editor of Reproductive Sciences (since 2014) and Human Reproduction (2005-2008). She convenes the Human Reproduction Module in the Bachelor of Biomedical Science course at Monash University.
  • Emeritus Professor Richard Smallwood AO, MB, BS, MD, FRACP, FRCP, FACP (Hon) (Non-Executive Director)

    Professor Smallwood is Emeritus Professor of Medicine, University of Melbourne. As Professor of Medicine within the University of Melbourne, he was Head of the Department of Medicine, Chairman of the Division of Medicine and Director of Gastroenterology at the Austin and Repatriation Medical Centres. Professor Smallwood was President of the Royal Australasian College of Physicians from 1996 to 1998 and was Chief Medical Officer of Australia from 1999 to 2003.

    Professor Smallwood has served as a chair of a large number of organisations including the NH&MRC, the National Influenza Pandemic Advisory Council, the National Health Information Management Advisory Council, the National Health Priority Action Council, the National Blood Authority and the Ministerial Taskforce for Cancer in Victoria.  Professor Smallwood is currently President of the Australian Medical Council. He was until 2010 a member of the Board of Governance of the Victorian Health Promotion Foundation and, until 2009, a director of the Murdoch Children’s Research Institute.  He was a director of the Australian Stem Cell Centre.

  • Dr Peter Riddles BSc (Hons), PhD, Grad Dip Bus (Management), FAICD (Non-Executive Director)

    Dr Riddles has extensive experience in biotechnology having served as director on many start-up enterprises, and having worked with universities and with the private sector. He is presently Chairman of the Griffith University Enterprise Board, Dosimetry and Imaging Pty Ltd, the CRC for Wound Management Innovation and Wound Management Pty Ltd. In addition he serves on the boards of Innovation Australia (including Chair of its Innovation Grants Committee), the Alberta Research and Innovation Authority (Canada), the Queensland Government Industry Advisory Group, is Chairman of the Steering Group for the Australian and New Zealand Biotechnology Fund (New Zealand) and is the inaugural Chairman of Life Sciences Queensland. He is presently the Director of ViciBio Pty Ltd that provides services to organisations involved in science, technology commercialisation and innovation. He was a director of the Australian Stem Cell Centre.

    Earlier, he was Chairman of Healthlinx Ltd, Chairman and Founder of AusBiotech Ltd, Chairman of the Queensland Biotechnology Advisory Committee and a member of the QUT Faculty of Science Advisory Committee.

  • Mr David Collins MEng, MBA, CA, GAICD MIET (Non-Executive Director)

    Mr Collins was Chief Executive Officer of the Australian Stem Cell Centre from September 2009 until November 2011. Prior to joining the ASCC, Mr Collins held a number of senior finance roles across a range of industries in Europe.


Day-to-day management of the Foundation is provided by an  Executive Officer and a Company Secretary as below:


Ms Julia Mason BA & BComm (Melb), Grad. Dip. Applied Finance and Investment, MBA (Chicago), MAICD, F Fin.
(Executive Officer)

Julia has a more than 20 year career focused on creating growth and value, in the private and not for profit sectors in both Australia and Asia, across the advertising, finance, and oil industries. Having held senior commerce and finance positions at Sensis and BP, Julia has deep business knowledge developed through a career in key business functions: finance, corporate strategy, corporate advisory, and marketing. Julia Ms Mason is a director of the Transport Accident Commission (TAC) Board of Victoria and was previously Chairman of the Victorian State Emergency Services (VICSES), One in Five, and a director with VicUrban. Julia also taught corporate finance in the masters programme with FinSia, the former Securities Institute of Australia. Julia was previously a director with SBDO, a Melbourne-based private equity business sourcing operational expertise and capital to back growth businesses.

Mr Graeme Mehegan BBus(Acc), FCPA, FCIS (Company Secretary)

Mr Mehegan was Chief Financial Officer for the Australian Stem Cell Centre from August 2009 until November 2011. He was Chief Financial Officer and Company Secretary for Pioneer Electronics Australia from January 2001 until March 2008 and prior to that held senior financial roles (including the position of Company Secretary) with Random House Australia and Pitman Publishing, both in the book publishing industry.


We aim to:

  • Promote the study and use of stem cells

  • Prevent or control diseases or illness

  • Enhance public education about stem cells